Exhibit 99.1 Zevia Announces Fourth Quarter and Full Year 2025 Results; Appoints Lead Independent Director, Andrew Ruben, to Chair of the Board LOS ANGELES – February 25, 2026 (BUSINESS WIRE) – Zevia PBC ("Zevia" or the "Company") (NYSE: ZVIA), the Company bringing naturally delicious, zero sugar, clean-label beverages, today reported results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 Highlights Full Year 2025 Highlights "2025 was a pivotal year for Zevia. We gained ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-34571 PEBBLEBROOK HOTEL TRUST (Exact Name of Registrant as Specified in Its Charter) Maryland 27-1055421 (State of Incorporation or Organizatio ...

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________________________ __________________________________________________________________________________________________FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37534 PLANET FITNESS, INC. (Exact name of Registrant as specified in its Charter) Delaware 38-3942097 (State or Other Jurisdiction of In ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year enDdecdember 31, 2025 Energy Recovery, Inc. (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incorporation) (I.R.S. Employer Identification No.) Delaware 01-0616867 1717 Doolittle Drive San Leand,rCoalifornia94577 (Address of Principal Executive Offices) (Zip Code) ☐ TRANSITI ...

Financial Performance - Arcus reported revenues of $33 million for Q4 2025, a decrease from $36 million in Q4 2024, with $23 million from Gilead collaboration and $7 million from Taiho's option exercise[17]. - The net loss for Q4 2025 was $106 million, compared to a net loss of $94 million in Q4 2024[17]. - Total revenues for Q4 2025 were $33 million, a decrease of 8.3% from $36 million in Q4 2024[22]. - Basic and diluted net loss per share improved slightly to $(0.89) in Q4 2025 from $(1.03) in Q4 2024[22]. - GAAP revenue for the full year 2026 is projected to be between $45 million and $55 million[17]. Research and Development - Research and Development (R&D) expenses increased to $121 million in Q4 2025 from $111 million in Q4 2024, driven by higher late-stage development costs[17]. - Arcus anticipates a decrease in R&D expenses for the full year 2026 compared to 2025, influenced by the results of the futility analysis of the STAR-121 study[17]. - Research and development expenses for the year ended December 31, 2025, were $523 million, up from $448 million in 2024, indicating a continued focus on innovation[22]. - The Phase 3 PEAK-1 study for casdatifan is currently enrolling globally, targeting a peak sales opportunity exceeding $5 billion in the IO-experienced and first-line settings[3]. - Casdatifan demonstrated a median progression-free survival (PFS) of 15.1 months and a confirmed overall response rate (cORR) of 45% in late-line kidney cancer[6]. - Arcus plans to initiate a Phase 3 study for casdatifan in a TKI-free combination by the end of 2026, focusing on first-line metastatic settings[6]. - The company expects to advance its first inflammation program, a potential oral MRGPRX2 antagonist, into clinical development in 2026[12]. Financial Position - Arcus has $1.0 billion in cash, cash equivalents, and marketable securities as of December 31, 2025, up from $992 million in 2024, providing a cash runway until at least the second half of 2028[17]. - Cash, cash equivalents, and marketable securities increased to $1,010 million as of December 31, 2025, compared to $992 million a year earlier[24]. - Total assets decreased to $1,139 million in 2025 from $1,150 million in 2024[24]. - Total liabilities decreased significantly from $665 million in 2024 to $508 million in 2025, indicating improved financial health[24]. - Total stockholders' equity increased to $631 million in 2025, up from $485 million in 2024, reflecting a strong capital position[24]. Operating Expenses - Total operating expenses rose to $147 million in Q4 2025, up from $139 million in Q4 2024, primarily driven by increased research and development costs[22].

Financial Performance - Fourth quarter revenue reached $225.4 million, representing a 23% year-over-year increase, contributing to a full-year revenue of $836.6 million, up 22% year-over-year [2]. - GAAP net income for Q4 was $14.0 million, or $0.19 per diluted share, a decrease of 64% compared to the previous year, while full-year net income was $48.7 million, or $0.64 per diluted share [5]. - Adjusted EBITDA for Q4 was $36.7 million, a 19% increase year-over-year, while full-year adjusted EBITDA reached $145.0 million [5]. - Net income for the year ended December 31, 2025, was $48.7 million, a 60% increase from $30.4 million in 2024 [21]. - Non-GAAP operating income for the year ended December 31, 2025, was $96.0 million, a 102% increase from $47.6 million in 2024 [30]. - Adjusted EBITDA for the year ended December 31, 2025, reached $145.0 million, a 35% increase from $107.9 million in 2024 [30]. - The company expects 2026 annual GAAP operating income to be in the range of $72-$89 million and non-GAAP operating income to be in the range of $95-$110 million [33]. - GAAP operating income is projected to be between $22 million and $27 million for the first quarter of 2026 [35]. - Non-GAAP operating income is expected to range from $28 million to $32 million for the first quarter of 2026 [35]. - Full year 2026 GAAP operating income is anticipated to be between $72 million and $89 million [35]. - Full year 2026 non-GAAP operating income is expected to be in the range of $95 million to $110 million [35]. Revenue Breakdown - Loans revenue surged 141% year-over-year to $42.3 million, driven by growth in personal and mortgage loans [6]. - Insurance revenue increased by 13% year-over-year to $81.2 million, primarily due to expanded budgets for auto insurance products [6]. - Credit card revenue decreased by 24% year-over-year to $26.5 million, attributed to ongoing challenges in organic search traffic [6]. - SMB products revenue fell 12% year-over-year to $22.5 million, also impacted by organic search traffic headwinds [6]. - Revenue is expected to be in the range of $224-$232 million, representing a 9% year-over-year increase at the midpoint [36]. Cash and Investments - Cash and cash equivalents increased by 48% year-over-year to $98.3 million [7]. - The company reported a net increase in cash and cash equivalents of $32.0 million for the year ended December 31, 2025 [21]. - Adjusted free cash flow for the year ended December 31, 2025, was $117.8 million, compared to $48.5 million in 2024, indicating a significant increase [32]. - Capitalized software development costs for the year ended December 31, 2025, were $16.9 million, down from $20.7 million in 2024 [32]. Operational Metrics - The operating income margin for the year ended December 31, 2025, was 8%, compared to 1% in 2024 [30]. - The company reported a non-GAAP operating income margin of 11% for the year ended December 31, 2025, up from 7% in 2024 [30]. Future Outlook - The company is unable to provide a quantitative reconciliation of forecasted GAAP net income to forecasted adjusted EBITDA due to uncertainties in certain reconciling items [34]. - The company faces significant risks and uncertainties that may cause actual results to differ materially from forward-looking statements [39]. - The company aims to grow traffic, engagement, and monetization on its platform while expanding within existing and new verticals [41]. - The company is focused on developing scalable technology and enhancing user engagement through personalized guidance [41]. Shareholder Returns - The company announced a $100 million increase in its share repurchase program, bringing the total authorized amount to $225 million [14]. Reporting Changes - Effective Q1 2026, revenue will be reported by user groups: Consumer and SMB, aligning with management's evaluation of financial performance [10].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 001-39186 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Inco ...

Revenue Projections - Veracyte expects total revenue for Q4 2025 to be between $138 million and $140 million, with testing revenue between $134 million and $136 million[5]. - For the full year 2025, Veracyte expects total revenue between $515 million and $517 million, with testing revenue between $491 million and $493 million[5]. Testing Volume - The company anticipates testing volume of approximately 45,500 tests for Q4 2025[5]. - The projected testing volume for the full year 2025 is approximately 169,700 tests[5]. Financial Metrics - Veracyte expects an adjusted EBITDA margin of greater than 25% for the full year 2025[5]. - The company is unable to provide an estimate of net income margin for the full year 2025 due to the unavailability of reliable estimates[6]. - Key components affecting net income margin may include stock-based compensation expenses and acquisition-related expenses[6]. Financial Reporting - The preliminary financial results are subject to completion of financial closing procedures and audit adjustments[6]. - Veracyte's audited financial statements for the full year ended December 31, 2025, are not yet available[6]. - The press release regarding these results was issued on January 11, 2026[5].

CONTACT: Brendon Frey Brendon.frey@icrinc.com HAMILTON BEACH BRANDS HOLDING COMPANY ANNOUNCES FOURTH QUARTER AND FULL YEAR 2025 RESULTS Fourth Quarter Revenue Relatively Flat at $212.9 Million Fourth Quarter Gross Margin Expands 220 Basis Points Fourth Quarter Operating Profit Grows 8.0% to $25.4 Million Selling, general and administrative expenses (SG&A) increased to $34.7 million compared to $32.1 million. The increase was primarily driven by higher performance-based compensation expense related to improv ...